Cutaneous T-cell lymphoma (CTCL) has been suggested by in vitro experiments to represent a malignant CD4 þ T-cell proliferation with a regulatory T-cell (Treg) phenotype (CD4 þ CD25 þ FOXP3 þ ). We investigated percentages of FOXP3 þ and CD25 þ cells in the blood of 15 Sé zary, 14 mycosis fungoides (MF), and 10 psoriasis (Pso) patients and 20 normal healthy donors (NHDs). We found similar numbers of FOXP3 þ cells in MF (10.4% of blood CD4 þ cells) and Pso (11.1%) patients and NHDs (9.8%). In 8 of 15 (53%) Sé zary patients, significantly reduced percentages of FOXP3 þ cells were seen in blood (2.9%) and skin (10.4%). Interestingly, 6 of 15 (40%) Sé zary patients showed significantly increased percentages of FOXP3 þ cells (39.7% (blood), 20.3% (skin)); however, these cells did not express CD25. In these latter patients, clone-specific TCR-Vb-chain antibodies were used to demonstrate that these FOXP3 þ CD25 À cells were monoclonal CTCL tumor cells. FOXP3 þ CD25 À CTCL tumor cells showed a highly demethylated status of the foxp3 gene locus similar to Treg cells, and they were functionally able to suppress IL-2 mRNA induction in TCR-stimulated conventional T cells. Thus, FOXP3 þ CD25 À CTCL tumor cells with functional features of Treg cells define a subgroup of Sé zary patients who might carry a different prognosis and might require differential treatment.
INTRODUCTION
Primary cutaneous T-cell lymphomas (CTCLs) represent a heterogeneous group of rare lymphoproliferative disorders characterized by skin-homing monoclonal proliferations of CD4 þ T lymphocytes (Willemze et al., 2005) . The major variant is mycosis fungoides (MF), which is confined to the skin and has a slowly progressing course over years to decades. The less common Sézary syndrome (SS) carries a worse prognosis (Klemke et al., 2005) and is characterized by erythroderma, generalized lymphadenopathy, and leukemic blood involvement with 41000 Sézary cells per ml (Vonderheid et al., 2002) . Both variants of CTCL are clinically associated with a marked immunosuppression that is often associated with a fatal outcome, especially in patients with SS.
In 1995, Sakaguchi et al. identified CD4 þ CD25 þ T cells that control immune responses to non-self antigens by suppressing conventional T-cell (Tcon) activity (Sakaguchi et al., 1995) . These suppressive cells represent a small subset of T cells (approximately 10% of peripheral CD4 þ T cells) and were termed regulatory T (Treg) cells Sakaguchi and Powrie 2007) . Treg cells are important because depletion of CD25 þ cells leads to a variety of autoimmune inflammatory diseases, whereas reconstitution with CD4 þ CD25 þ T cells can inhibit disease development (Setoguchi et al., 2005) . In 2001, research on scurfy mice, which spontaneously develop severe autoimmunity, showed that the disease was due to a single mutation of the foxp3 gene on the X chromosome . Mutations of the human foxp3 gene were found to be the cause of a similar human disease called IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome) (Bennett et al., 2001) . FOXP3 is abundantly expressed in natural Treg cells, and is so far the most reliable molecular marker for these cells (Roncador et al., 2005) . However, naive T cells in humans readily express FOXP3 upon TCR stimulation, although the expression is generally much lower and only transient compared with that of natural Treg cells (Gavin et al., 2006; Pillai et al., 2007; Walker et al., 2003; Yagi et al., 2004) . Still, quantifying the degree of DNA demethylation in the foxp3 locus enables differentiation between Treg cells and activated FOXP3 þ Tcon cells (Baron et al., 2007; Janson et al., 2008) .
Despite their importance in controlling autoimmunity, Treg cells can also suppress antitumor immune responses in various cancers . Therapeutically, antitumor immune responses can be enhanced after depletion of Treg cells during vaccination, for example, in glioma patients (Grauer et al., 2008) . Not only solid tumors but also non-Hodgkin lymphomas can induce functional Treg cells and thus worsen prognosis (Mittal et al., 2008) .
The fact that CTCL is a disease of malignant CD4 þ T cells associated with clinically evident immunosuppression made it an interesting model for the investigation of various immune functions. On the basis of in vitro cell culture studies, Berger et al., 2005 suggested that CTCL represents a malignant proliferation of Treg cells, which could explain its immunosuppressive nature. This could not be immediately confirmed in vivo, as multiple laboratories, including our own, failed to demonstrate the FOXP3 expression of skin-infiltrating CTCL tumor cells and, rather, showed that FOXP3 þ cells in MF skin lesions were bona fide Treg cells (Banham et al., 2008; Gjerdrum et al., 2007; Klemke et al., 2006) . High numbers of FOXP3 þ cells in skin specimens from MF lesions correlated with early stages of MF and a better prognosis than did MF skin infiltrates with fewer FOXP3 þ cells (Gjerdrum et al., 2007) . However, a recent study identified FOXP3 þ CTCL tumor cells in the skin of 4 of 11 patients and the expression of low-molecular splice forms of FOXP3 in the peripheral blood of 4 of 6 patients with SS (Krejsgaard et al., 2008) .
Here, we characterized Treg cells in the peripheral blood of 29 CTCL patients by analyzing the expression of FOXP3, CD25, and skin-homing markers. In a subgroup comprising 40% of our Sézary patients, we found FOXP3 mRNA and protein expressions of CTCL tumor cells, which were identified by monoclonal TCR-Vb-chain expression. FOXP3 þ CTCL tumor cells showed a highly demethylated status of the foxp3 gene locus, similar to Treg cells. Finally, FOXP3 þ CTCL tumor cells isolated from Sézary patients also showed regulatory functions like those of Treg cells, as demonstrated by the suppression of IL-2 mRNA induction in TCR-stimulated Tcon cells.
RESULTS
CD4 þ CD25 þ FOXP3 þ cells are not significantly reduced in the peripheral blood of patients with SS compared with MF, psoriasis, and healthy controls To identify Treg cells in the peripheral blood of CTCL patients and controls (normal healthy donors (NHDs) and psoriasis (Pso)), we measured CD4, CD25, and FOXP3 expression by flow cytometry, according to the strategy presented in Supplementary Figure S1. In our previous study, we found a lack of Treg cells in Sézary patients, as demonstrated by the CD4 þ CD25 þ þ expression in the blood and the FOXP3 expression in the skin (Klemke et al., 2006) . To better characterize Treg cells in CTCL patients, we analyzed FOXP3 expression in the blood from Sézary and MF patients and, as controls, from Pso patients and NHDs. We found similar percentages of FOXP3 þ cells in NHDs (9.8±2.9% (SD) of CD4 þ cells, n ¼ 20), MF (10.4 ± 5.4%, n ¼ 14) and Pso (11.1 ± 6%, n ¼ 10) patients. Percentages of FOXP3 þ CD25 þ þ cells in NHDs (2.9 ± 1.3%), MF (3.1 ± 3.2%) and Pso (3.7 ± 4.3%) patients were also comparable (Figures 1a and b, Table 1 ). In line with our previous findings (Klemke et al., 2006) , the percentages of FOXP3 þ (4.4 ± 23,9%, n ¼ 15) and FOXP3 þ CD25 þ þ cells (0.4±2.4%) were reduced in Sézary patients (Figures 1a and b ). However, these differences were not significant because of the wide spread of values in the Sézary group.
Sézary patients show heterogeneous expression levels of FOXP3 in peripheral blood and skin
A more detailed analysis of the Sézary patient group revealed two different subgroups. In all, 53% (8 of 15) of Sézary patients showed significantly reduced percentages of FOXP3 þ (2.9±1.3% of CD4 þ cells) and FOXP3 þ CD25 þ þ cells (0.3±0.8%) (''SS FOXP3 low'') when compared with those from NHDs (both Po0.05) and Pso and MF patients. Interestingly, 40% (6 of 15) of Sézary patients showed significantly increased numbers of FOXP3 þ cells (39.7 ± 21.6%, n ¼ 6) (''SS FOXP3 high''), and a subset of these also had increased percentages of FOXP3 þ CD25 þ þ cells (5.2± 0.8%, n ¼ 3) in comparison with those from NHDs (both Po0.05) (Figures 1c and d) . Figures 2a and b show original flow cytometry data in order to illustrate the varying levels of FOXP3 þ cells in CD4 þ cells in different patients. In patient SS1, we hardly detected any FOXP3 þ cells, and the few that were found were CD25 À (Figure 2a ). In patient SS9, nearly all CD4 þ cells expressed FOXP3 at levels almost as high as those in regular Treg cells (as can be noticed by the overlay of CD4 þ cells from an NHD, Figure 2b ). Finally, in some patients, for example, SS12, half of the CD4 þ cells were FOXP3 þ . Interestingly, almost all FOXP3 þ cells of the patients were CD25 À , and the few FOXP3 þ CD25 þ cells detected probably reflect bona fide Treg cells. Only in patients SS4, SS11, and SS15 did we find substantial levels of CD25 on FOXP3 þ cells. In addition, the percentage of FOXP3 þ cells also differs in the skin between the two Sézary patient groups, with a trend toward higher percentages of skin-infiltrating FOXP3 þ cells for the ''SS FOXP3 high'' group (Table 1) . ''SS FOXP3 high'' patients have a mean of 20.3 ± 8.2% (range 11-31%) FOXP3 þ cells of CD4 þ cells in the skin infiltrate in contrast to a mean of 10.4±5.3% (range 7-18%, P ¼ 0.063) FOXP3 þ cells of CD4 þ cells in patients of the ''SS FOXP3 low'' group. This finding suggests that in the ''SS FOXP3 high'' patients, CTCL tumor cells may express FOXP3 in vivo, similar to what has been shown by Berger et al., 2005 for CTCL cells after in vitro culture with dendritic cells.
A subgroup of patients with SS has high numbers of FOXP3 þ CTCL tumor cells in the peripheral blood
The high number of FOXP3 þ cells in the blood of almost half of the Sézary patients could be due to FOXP3 expression in monoclonal CTCL tumor cells or to the expansion of polyclonal natural Treg cells. To distinguish between these possibilities, each Sézary patient was screened with a panel of TCR-Vb-chain antibodies as described elsewhere (Morice et al., 2004) . We were able to detect a predominant T-cell population by an identical TCR-Vb-chain expression in 11 of 15 (73%) Sézary patients (Table 1) as described previously, because the panel of available TCR-Vb-chain antibodies covers only about 70% of the TCR-Vb-chain repertoire (Klemke et al., 2008; Morice et al., 2004; Morice et al., 2006) . In some Sézary patients, the CTCL tumor cells as identified by the identical ''clonal'' TCR expression also express FOXP3 ( Figure 3 ), but, interestingly, express very low levels of CD25 (data not shown). In an NHD, as well as in patient SS3, (Figure 3c ). Finally, a high FOXP3 expression of all CTCL tumor cells was seen in patient SS12 (Figure 3d ). This finding was verified by staining with two different FOXP3 antibodies (PCH101 and 236A/E/), confirming its specificity (Tran et al., 2007) (Figure 3 ). Furthermore, we excluded nonspecific Ab binding using isotype control antibodies (data not shown). Finally, we were able to identify increased Foxp3 mRNA expression levels in TCR-Vb-chain CTCL tumor cells of ''SS FOXP3 high'' patients that were sorted by fluorescence-activated cell sorting (FACS), which were similar to those in expanded Treg cells from NHD, although lower than in freshly isolated Treg cells from NHD ( Figure 4 ). Furthermore, the Foxp3 mRNA expression levels of ''SS FOXP3 high'' patients were similar to those of Tcon cells stimulated with a-CD3/a-CD28 for 15-23 hours. However, the FOXP3 mRNA expression in activated Tcon cells was only transient and decreased below that of unstimulated Tcon cells after 14 days ( Figure 4 ). FOXP3 protein expression was also seen in stimulated Tcon cells, but to a lesser extent than in Treg cells ( Figure 2c ). In addition, FOXP3 expression is stable in CTCL tumor cells, as reanalyses of FOXP3 protein expression in several FOXP3 þ patients after a few months still yielded an identically high FOXP3 expression in tumor cells (data not shown). In contrast to this, the FOXP3 expression in Tcon cells was shown to be only transient after in vitro activation (Figure 4 and Allan et al., 2007; Pillai et al., 2007 and Walker et al., 2003) . Patients belonging to the ''SS FOXP3 low'' group were found to express low levels of FOXP3 mRNA similar to shortly stimulated (3 hours) or unstimulated Tcon cells from NHDs (Figure 4 ). In summary, this clearly shows that in a subgroup of 40% of Sézary patients, CTCL tumor cells express FOXP3 mRNA and protein. Figure 5a ). In contrast, ''SS FOXP3 low'' patients showed a similar methylation status of the foxp3 gene locus, as did Tcon cells from NHDs (Figure 5a ). Demethylation in FOXP3 þ tumor cells can be observed although the analyzed patients are all female, even though one of the X-chromosomal foxp3 loci is usually silenced and thus methylated. An aberrant methylation pattern does not seem to be a general feature of Sézary tumor cells, as it is observed only in FOXP3 þ and not in FOXP3 À tumor samples. Recently our group demonstrated that Treg cells suppress the induction of Th1 cytokine mRNA (for example, IL-2 and IFN-g) of Tcon cells as early as 1 h after stimulation (Oberle et al., 2007) . Here, we tested the capacity of CTCL tumor cells from both patient groups to suppress IL-2 mRNA induction of Tcon cells after TCR stimulation. TCR-Vb-chain FACS-sorted FOXP3 þ CTCL tumor cells suppressed TCRinduced IL-2 mRNA expression in Tcon cells to a similar extent, as did naturally occurring Treg cells from NHDs (Figure 5b) . In contrast, FOXP3 À CTCL tumor cells from patients of the ''SS FOXP3 low'' group were not able to suppress TCR-induced IL-2 mRNA induction in Tcon cells (Figure 5b) . Thus, FOXP3 þ CTCL tumor cells have suppres-sive function and a demethylated foxp3 gene locus, and are therefore similar to naturally occurring Treg cells.
DISCUSSION
In this study, we provide evidence for FOXP3 þ CTCL tumor cells in vivo. In accordance with our previous results showing a lack of CD4 þ CD25 þ cells in Sézary patients (Klemke et al., 2006) , we identified a subgroup of Sézary patients with significantly reduced percentages of FOXP3 þ and FOXP3 þ CD25 þ cells in peripheral blood in contrast to MF and Pso patients and NHDs. Interestingly, 40% of Sézary patients presented significantly increased numbers of FOXP3 þ and FOXP3 þ CD25 þ cells in the blood, and also- to a lesser degree-in the skin. This could be attributable to the fact that the majority of skin biopsies were taken at the time of diagnosis, in contrast to most of the blood samples, which were taken during the course of disease in order to obtain fresh cells for flow cytometry and functional assays. Our finding of FOXP3 þ CTCL tumor cells supports and extends a study that identified increased FOXP3 protein and mRNA expression in the peripheral blood of 6 of 31 (20%) Sézary patients (Capriotti et al., 2008) . This retrospective study did not correlate FOXP3 expression with tumor cell markers and did not analyze skin specimens. Krejsgaard et al. (2008) used immunohistochemistry to detect the FOXP3 expression of skin-infiltrating CTCL tumor cells-identified by morphology-and low-molecular splice forms of FOXP in the peripheral blood of Sézary patients. In our study, we identified FOXP3 protein and mRNA expression in clonally expanded CTCL tumor cells by using clone-specific TCR-Vbchain antibodies for co-stainings. Similar to our results in Sézary patients, it was shown in several studies that adult T-cell leukemia/lymphoma cells express FOXP3 (Chen et al., 2006; Karube et al., 2004; Karube et al., 2008; Kohno et al., 2005; Matsubara et al., 2005; Shimauchi et al., 2008; Abe et al., 2008) . Interestingly, some patients with adult T-cell leukemia/lymphoma show clinical features similar to those of patients with MF (Willemze et al., 2005) . The FOXP3 expression of adult T-cell leukemia/lymphoma tumor cells was shown to correlate with infection by human T-lymphotropic virus-1 (Walsh et al., 2006) . Infection with Epstein-Barr virus might also lead to FOXP3 þ tumor cells, as observed in patients with posttransplant lymphoproliferative disorder (Ebert et al., 2008) . However, infections with human T-lymphotropic virus-1 and Epstein-Barr virus are usually not seen in Sézary patients. FOXP3 expression of tumor cells was recently also shown for a number of solid tumors, including malignant melanoma, prostate cancer, colon cancer, and, less frequently, in breast cancer cell lines (Ebert et al., 2008) . Thus, FOXP3 expression is not restricted to Treg cells but is also seen in various tumor cells.
CTCL tumor cells represent monoclonal proliferations of CD4 þ lymphocytes. Treg cells were shown to be a subpopulation of CD4 þ lymphocytes, characterized by either unstimulated (unstim.) or stimulated, were used as control. To exclude cell density effects, double amounts of Tcon cells alone were also used as control (not shown). Treg cells were isolated by flow sorting for expression of CD4 and high expression of CD25, whereas Tcon cells were CD25 depleted and CD4 þ purified by MACS technology. After the co-culture assays, responder Tcon cells were separated from Treg cells by staining for CD4 and CD25 and from tumor cells by CD4 and TCR-Vb staining and subsequent flow sorting. After stimulation with a-CD3 and a-CD28 for 5 hours, only Treg cells express CD25, whereas Tcon cells are not yet positive for the activation marker, CD25, on the surface. RNA was extracted from the responder Tcon cells and subjected to quantitative reverse transcriptase-PCR. IL-2 mRNA expression, normalized to glyceraldehyde-3-phosphate dehydrogenase, is shown relative to unstimulated Tcon cells (set to 1). Error bars represent standard deviations of the mean. Subgroups of SS patients are labeled with ( þ ) for ''SS FOXP3 high'' or (À) for ''SS FOXP3 low.'' n. a., not amplified.
FOXP3 and CD25 expression. Therefore, the question was whether CTCL tumor cells in Sézary patients also express CD25. We failed to detect high expression levels of CD25 in the majority of patients, as almost all FOXP3 þ cells of the patients were CD25 À . Only in three patients did we find substantial levels of CD25. Although FOXP3 binds to the CD25 promoter and is therefore capable of inducing CD25 expression, FOXP3 þ CD25 À cells with suppressive function were also found in mice (Masteller et al., 2005; Wan & Flavell 2005; Fontenot et al., 2003) . It could be speculated that control of the CD25 promoter by FOXP3 is lost in CTCL tumor cells. Furthermore, Capriotti et al. (2008) presented similar results in Sézary patients with a high tumor burden. In their study, 8 of 31 Sézary patients showed CD25 expression that did not always correlate with FOXP3 expression. The expression of CD25 by circulating neoplastic cells of leukemic CTCL seems to be low and quite variable (Jones et al., 2004; Talpur et al., 2006; Waldmann et al., 1984) . The quantification of Foxp3 mRNA underscored our protein data in that only ''SS FOXP3 high'' cells expressed substantial amounts of Foxp3 mRNA. Foxp3 mRNA expression of those tumor cells was not as high as that in freshly isolated Treg cells from NHD, but it was comparable to that in Treg cells from NHDs, which were expanded in vitro for 2-3 weeks, and to Foxp3 mRNA expression levels detected in 15-23-hour TCR-stimulated Tcon cells. These data might be indicative of a high expansion rate of CTCL tumor cells in vivo.
CTCL tumor cells might have acquired FOXP3 expression by activation. It was recently shown and confirmed by us (Figures 2c and 4) that activated human Tcon cells transiently express FOXP3 (Allan et al., 2007) and can gain suppressive abilities (Pillai et al., 2007 and Walker et al., 2003) . Other investigators have shown that FOXP3 expression does not correlate with suppressive function (Tran et al., 2007 and Zheng et al., 2008) . Baron et al. (2007) found that DNA demethylation of the foxp3 locus discriminates Treg cells from activated FOXP3 þ Tcon cells in that several regions of the foxp3 locus are demethylated in Treg, but methylated in Tcon cells. In particular, the TSDR (Tregspecific demethylated region) of the foxp3 gene, which consists of amplicon 5, was shown to be highly demethylated, specifically in Treg cells. Representative patients expressing FOXP3 exhibit a stronger demethylation of the foxp3 locus than do Tcon and FOXP3 À CTCL tumor cells, the latter carrying a methylation pattern resembling the one of Tcon cells. This indicates that the FOXP3 expression observed in CTCL tumor cells in the ''SS FOXP3 high'' group of Sézary patients is due to the regulation of foxp3 gene transcription and not (only) to altered stability of FOXP3 mRNA or protein. Another group demonstrated that the features of Treg cells (FOXP3 expression and IL-10 production) were induced in CTCL tumor cells by common g-chain-signaling cytokines, such as IL-2 and IL-15, and do not represent a fully predetermined, constitutive phenotype independent of the local environmental stimuli to which these malignant CD4 þ T cells become exposed, for example, in the skin (Kasprzycka et al., 2008) .
To determine whether FOXP3 þ CTCL tumor cells represent a malignant proliferation of Treg cells, functional studies of their suppressive capacity are crucial. Because CTCL tumor cells are difficult to cultivate in vitro, long-term assays to assess suppressive activity, such as proliferation assays, are difficult to perform. Therefore, we tested suppressive capacity by analyzing IL-2 mRNA suppression, which was shown to be suppressed in Tcon cells by Treg cells within a few hours (Oberle et al., 2007) . FOXP3 þ CTCL tumor cells from the ''SS FOXP3 high'' subgroup of patients were able to suppress IL-2 mRNA induction in TCRstimulated Tcon cells in contrast to FOXP3 À CTCL tumor cells, which failed to do so. This clearly shows that FOXP3 expression of CTCL tumor cells is associated with Treg-like functions. The functional relevance of FOXP3 expression for the suppression of Tcon cells could be demonstrated in some patients with adult T-cell leukemia/lymphoma (Chen et al., 2006; Matsubara et al., 2005) , but not in others (Shimauchi et al., 2008) . It remains an open question whether FOXP3 þ CTCL tumor cells are capable of suppressing an antitumor immune response. However, normal Treg cells might control tumor cell growth in CTCL patients, as reflected by the association of high numbers of Treg cells with a better prognosis in patients with MF and CD30 þ CTCL (Gjerdrum et al., 2007; Gjerdrum et al., 2008) , in contrast to the more aggressive course observed in Sézary patients who lack normal Treg cells (Klemke et al., 2006) or exhibit Treg cells without suppressive activity (Tiemessen et al., 2006) . Extracorporeal photopheresis has been used to treat SS for more than 20 years. It was shown to induce antigen-specific Treg cells in mice (Maeda et al., 2005) , further supporting a beneficial effect of Treg cells in the prognosis, course, and treatment of CTCL. It can be speculated that TCR-specific Treg cells might be able to specifically suppress the growth of CTCL tumor cells and thereby control tumor-cell expansion in the skin. This would be supported by the observation of a better prognosis for CTCL patients with increased numbers of Treg cells. In nonlymphoid cancer, Treg cells will not have a direct influence on tumor cells, but they will inhibit the T cells that should fight the cancer. In CTCL, it is possible that a direct effect of Treg cells on tumor cells outweighs their suppressive effect on the immune system in general.
The FOXP3 þ CTCL tumor cells behave in a manner functionally similar to Treg cells despite the fact that they exhibit phenotypical differences (for example, in CD25 expression). It remains an open question whether FOXP3 þ CTCL tumor cells acquired FOXP3 expression either during the natural course of the disease or because of the choice of treatment. In our study population, we identified two untreated Sézary patients with FOXP3 þ CTCL tumor cells ( Table 2) . The majority of patients in both groups received extracorporeal photopheresis and IFN-a, which makes it difficult to identify a particular therapy leading to FOXP3 expression in tumor cells. Another point of interest is the clinical relevance of our observation regarding prognosis and response to treatment. We compared different clinical parameters of ''SS FOXP3 low'' with ''SS FOXP3 high'' patients. We could not find significant differences between www.jidonline.org 2881 the two Sézary patient groups in CTCL severity index, tumor burden (CD4/CD8 ratio, number of circulating Sézary cells), and duration of disease. However, there seems to be a trend toward a better prognosis for the ''SS FOXP3 high'' group. In this population, one of six patients died, whereas four of eight patients in the ''SS FOXP3 low'' group died (Table 2) . Unfortunately, the two subgroups were too small for a statistical comparison. In patients with MF and CD30 þ CTCL, high numbers of skin-infiltrating FOXP þ cells were shown to be associated with a favorable prognosis (Gjerdrum et al., 2007; Gjerdrum et al., 2008) . Another study found a worse prognosis for Sézary patients with FOXP3 expression (Capriotti et al., 2008) . The clinical relevance of our findings needs to be confirmed in a larger cohort of well-characterized Sézary patients. The EORTC (European Organization for Research and Treatment of Cancer) cutaneous lymphoma task force is planning a multicenter study to evaluate diagnostic markers, including FOXP3, in SS, which could possibly answer the above-mentioned questions. According to the TNM classification (Bunn and Lamberg, 1979) . 3 In months. 4 According to Klemke et al. (2005) . 5 At the time of this study. Cut-off date: 31 March 2008.
In conclusion, in a subgroup of Sézary patients, CTCL tumor cells show FOXP3 expression and Treg-like functions, for example, foxp3 gene locus demethylation and suppression of IL-2 mRNA in TCR-stimulated Tcon cells. FOXP3 þ CTCL tumor cells differ from Treg cells in an inconsistent CD25 expression and a lower Foxp3 mRNA expression. The modulation of FOXP3 expression in leukemic T cells could be implicated in oncogenesis and potentially has a useful clinical role. It has to be elucidated whether the FOXP3 expression of CTCL tumor cells is of prognostic relevance, and whether FOXP3 expression is acquired or whether CTCL represents a malignant expansion of Treg cells. Thereafter, it should be possible to develop new treatment options that target CTCL tumor cells more specifically.
PATIENTS AND METHODS

Patients
A total of 29 CTCL patients diagnosed according to the WHO (World Health Organization)-EORTC classification of cutaneous lymphomas (Willemze et al., 2005) , the tumornode-metastasis staging classification (Bunn and Lamberg, 1979) , and the criteria of the International Society of Cutaneous Lymphomas (Vonderheid et al., 2002) were included in the study, representing MF stages IA (n ¼ 1), IB (n ¼ 12), and IVA (n ¼ 1) and SS stages III (n ¼ 7), IVA (n ¼ 7), and IVB (n ¼ 1) (Table 2) . For controls, we investigated blood samples from Pso patients (n ¼ 10) and NHDs (n ¼ 20). Informed consent was obtained from all participants before inclusion. The study was conducted according to the ethical guidelines at our institution and the Helsinki Declaration, and approved by the Ethics Committee II of the Ruprecht-Karls-University of Heidelberg, Germany.
Cell isolation, antibodies, flow cytometry, and histology
Peripheral blood lymphocytes were separated by Ficoll gradient centrifugation and monocyte depletion. The following antibodies were used for staining of the lymphocytes as previously described: a-CD4-PerCp, a-CD25-APC-Cy7 (BD Pharmingen, Heidelberg, Germany), a-CLA-FITC (Miltenyi Biotec, Bergisch Gladbach, Germany), and a-FOXP3-APC (clones PCH101 and 236/E7, eBioscience, Heidelberg, Germany) (Fritzsching et al., 2005; Oberle et al., 2007) . Flow cytometry was carried out on a FACSCanto II (Becton Dickinson, Heidelberg, Germany), and data were analyzed using FACSDiva and CellQuest software (Becton Dickinson). For RNA and DNA analyses, cells were sorted using CD4, CD25, and TCR-Vb-chain (Immunotech/Beckman Coulter, Fullerton, CA) expression with a FACS DIVA sorter (Becton Dickinson). For suppression assays, Treg and Tcon cells were isolated using MACS technology by CD4 and CD25 expression (Miltenyi Biotec) (Fritzsching et al., 2005; Oberle et al., 2007) .
Skin biopsies were taken at the first presentation of the patients before onset of treatment and were fixed in formalin. Hematoxylin and eosin, CD4 (clone 1F6, Novocastra, Newcastle Upon Tyne, UK), and FOXP3 stainings were carried out as described elsewhere (Poenitz et al., 2003; Klemke et al., 2006; Roncador et al., 2005) . All specimens were blinded and analyzed as previously described (Djemadji-Oudjiel et al., 1996; Klemke et al., 2006) .
Cell culture
Freshly isolated T cells were cultured in X-Vivo-15 medium (Cambrex, Verviers, Belgium) supplemented with 1% Glutamax (Invitrogen, Karlsruhe, Germany). Treg cells were either used immediately or stimulated overnight with 1 mg ml À1 a-CD3 and 50 U ml À1 IL-2, or expanded for up to 3 weeks with 0.1 mg ml À1 a-CD3, 300 U ml À1 IL-2, and 1 mg ml À1 a-CD28, and re-stimulated every week.
DNA preparation and foxp3 promoter methylation analysis
Genomic DNA from freshly prepared, FACS-sorted cells was isolated using the DNeasy tissue kit (Qiagen, Hilden, Germany) following the manufacturer's protocol. Analysis of the DNA methylation status of the foxp3 locus was carried out using bisulfite sequencing by Epiontis, Berlin, Germany as previously explained (Baron et al., 2007) .
Suppression assay, RNA preparation, and quantitative FOXP3 and IL-2 reverse transcriptase-PCR
The assays were carried out as previously described (Oberle et al., 2007) . Briefly, freshly isolated HLA-A2 -CD4 þ CD25 -(Tcon) and HLA-A2 þ CD4 þ CD25 high (Treg) or CTCL tumor cells were cultured alone or together in a 1:1 ratio and stimulated with soluble a-CD3 (0.2 mg ml À1 ) and a-CD28 (0.5 mg ml À1 ) mAbs. After stimulation for 3-5 hours, the cells were labeled with antibodies against CD4, CD25, HLA-A2, and the respective TCR-Vb-chain for CTCL tumor cells, separated by cell sorting on a FACS DIVA, and immediately lysed in RNA extraction lysis buffer. RNA isolation, cDNA preparation, and quantitative PCR were performed as described elsewhere (Fritzsching et al., 2005; Oberle et al., 2007) .
Statistical analysis
Data are presented as individual values and as mean or median. The Wilcoxon signed-rank test was used to compare the results of the various patient groups, including multiple comparisons. The test was considered significant with Po0.05.
